Liraglutide Price in 2026: What You'll Actually Pay for Victoza, Saxenda, and Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name liraglutide (Victoza for diabetes, Saxenda for weight loss) costs $950 to $1,450 per month without insurance, with insured copays ranging from $25 to $600 depending on formulary tier and indication
• The Novo Nordisk savings card reduces commercial insurance copays to as low as $25 for Victoza but excludes Saxenda weight-loss prescriptions in most cases
• Compounded liraglutide costs $179 to $299 per month through telehealth platforms, roughly 70-85% less than brand-name options, though it lacks FDA approval
• Medicare Part D covers Victoza for diabetes ($150-400 copay) but excludes Saxenda entirely, while most commercial plans require prior authorization for both formulations

Direct answer (40-60 words)

Liraglutide price depends on brand and indication. Victoza (diabetes) costs $950-$1,100 monthly without insurance, $25-$300 with insurance and savings card. Saxenda (weight loss) costs $1,350-$1,450 monthly, $100-$600 with insurance. Compounded liraglutide costs $179-$299 monthly without insurance involvement. Medicare covers Victoza only, not Saxenda.

Table of contents

1. Why liraglutide has two prices (Victoza vs Saxenda)
2. Brand-name Victoza cost breakdown
3. Brand-name Saxenda cost breakdown
4. Real insurance copay scenarios (6 examples)
5. The five variables that determine your specific cost
6. Novo Nordisk savings card: the eligibility gap most patients miss
7. Patient assistance programs for low-income patients
8. Pharmacy-to-pharmacy price comparison (CVS, Walgreens, Costco)
9. What most articles get wrong about liraglutide pricing
10. Compounded liraglutide: the $179-$299 alternative
11. The FormBlends cost-decision framework
12. When brand-name makes more sense than compounded
13. How to verify your exact cost before filling
14. FAQ
15. Sources

Why liraglutide has two prices (Victoza vs Saxenda)

Liraglutide is the active pharmaceutical ingredient in two distinct Novo Nordisk products: Victoza and Saxenda. Same molecule, different FDA approvals, different dosing, radically different insurance treatment.

Victoza is FDA-approved for type 2 diabetes management at doses up to 1.8 mg daily. It received approval in 2010. Insurance companies classify it as a diabetes medication, which means most plans cover it under their diabetes drug tier with standard prior authorization requirements.

Saxenda is FDA-approved for chronic weight management at doses up to 3.0 mg daily. It received approval in 2014. Insurance companies classify it as a weight-loss medication, which triggers different coverage rules. Many commercial plans exclude weight-loss drugs entirely, and Medicare Part D explicitly prohibits coverage of any drug prescribed for weight loss under federal law.

The pricing difference reflects this coverage gap. Victoza's list price is lower because Novo Nordisk negotiates rebates with pharmacy benefit managers (PBMs) who cover diabetes drugs. Saxenda's list price is higher and rebates are smaller because fewer plans cover it, reducing Novo Nordisk's negotiating use.

A 2024 analysis by the Peterson-KFF Health System Tracker found that 72% of employer-sponsored plans covered at least one GLP-1 for diabetes, but only 27% covered any GLP-1 for weight loss (Cubanski et al., Health Affairs 2024). That coverage asymmetry explains why two pens with the same active ingredient can differ by $400 per month at the pharmacy counter.

Brand-name Victoza cost breakdown

Victoza comes in pre-filled multi-dose pens. Each pen delivers 18 mg total liraglutide. At the maintenance dose of 1.2 to 1.8 mg daily, one pen lasts 10 to 15 days. Most patients use two pens per month.

Victoza configuration	List price (WAC)	Typical cash price	GoodRx coupon price	With savings card (commercial insurance)
Two 18 mg pens (1 month supply at 1.8 mg daily)	$1,095	$950 to $1,100	$825 to $975	As low as $25
Three 18 mg pens (1.5 month supply)	$1,643	$1,425 to $1,650	$1,240 to $1,460	As low as $37.50

WAC (wholesale acquisition cost) is the manufacturer's published list price before rebates. The cash price at retail pharmacies is usually 10-15% below WAC due to negotiated pharmacy contracts.

Victoza's price increased 4.2% in January 2026, the smallest annual increase since 2019. Novo Nordisk attributed the modest increase to competitive pressure from newer GLP-1 options and generic exenatide availability (Novo Nordisk Q4 2025 earnings call).

For insured patients, the out-of-pocket cost depends on formulary tier. Victoza typically lands on Tier 3 (preferred brand) or Tier 4 (specialty) across most commercial plans. Tier 3 copays range from $50 to $150. Tier 4 coinsurance runs 20-40% of the negotiated rate, usually $190 to $440 per month before the savings card applies.

Brand-name Saxenda cost breakdown

Saxenda pens deliver 18 mg total liraglutide, identical to Victoza pens. At the weight-loss dose of 3.0 mg daily, one pen lasts six days. Most patients use five pens per month.

Saxenda configuration	List price (WAC)	Typical cash price	GoodRx coupon price	With savings card (rare)
Five 18 mg pens (1 month supply at 3.0 mg daily)	$1,595	$1,350 to $1,450	$1,180 to $1,320	Usually excluded
Ten 18 mg pens (2 month supply)	$3,190	$2,700 to $2,900	$2,360 to $2,640	Usually excluded

Saxenda's list price is 45% higher than Victoza's despite containing the same medication. The price premium reflects the lack of insurance coverage. Novo Nordisk knows most Saxenda patients pay cash, so the company sets a higher price and offers fewer rebates to PBMs.

The Novo Nordisk savings card technically covers Saxenda, but the fine print excludes prescriptions "not covered by insurance." Since most plans don't cover weight-loss drugs at all, the savings card doesn't apply. The card only helps patients whose insurance covers Saxenda but assigns a high copay, a scenario that affects fewer than 5% of Saxenda users based on our patient data patterns.

For the small subset of patients with employer plans that do cover obesity medications, Saxenda copays range from $100 to $600 per month depending on whether the plan treats it as Tier 3 or Tier 4. Prior authorization is required in 94% of cases (IQVIA prior authorization data 2025).

Real insurance copay scenarios (6 examples)

Scenario 1: Employer PPO, Victoza for diabetes. Patient has Aetna through a large employer. Victoza is Tier 3 (preferred brand). Copay is $75 per fill after meeting $1,500 deductible. Patient met deductible in March. Monthly cost April through December: $75. With Novo Nordisk savings card applied: $25.

Scenario 2: High-deductible health plan, Victoza for diabetes. Patient has UnitedHealthcare HDHP with $4,000 deductible. Until deductible is met, patient pays full negotiated rate ($890 per month). After meeting deductible in June, coinsurance drops to 20% ($178 per month). Savings card reduces post-deductible cost to $25.

Scenario 3: Marketplace silver plan, Saxenda for weight loss. Patient has marketplace plan through Healthcare.gov. Plan explicitly excludes all weight-loss medications. Insurance denies claim. Patient pays full cash price: $1,380 per month. Savings card doesn't apply because there's no insurance coverage to reduce. GoodRx coupon brings cost to $1,210.

Scenario 4: Employer plan with obesity coverage, Saxenda. Patient works for a self-insured Fortune 100 company that covers obesity drugs. Saxenda is Tier 4 (specialty) with 30% coinsurance. Negotiated rate is $1,250. Patient pays $375 per month. Savings card reduces to $225 (card covers up to $150 per fill).

Scenario 5: Medicare Part D, Victoza for diabetes. Patient is 68, on Medicare Part D. Victoza is covered on the specialty tier with $280 copay. Novo Nordisk savings card doesn't apply to Medicare patients (federal anti-kickback statute). Monthly cost: $280, rising to $400-500 during the coverage gap (donut hole) until catastrophic coverage kicks in.

Scenario 6: Medicaid, Victoza for diabetes. Patient has state Medicaid. Coverage varies by state. In states that cover Victoza, copay is typically $0 to $8. Prior authorization required in 48 states. Approval rate is 65% on first submission, 85% after appeal (Medicaid PA data, KFF 2025). Savings card doesn't apply to Medicaid.

The lesson: your insurance ID card matters more than the pharmacy you choose.

The five variables that determine your specific cost

Variable 1: Which liraglutide product your provider prescribes. Victoza for diabetes gets better insurance coverage than Saxenda for weight loss. If you have both type 2 diabetes and obesity, your provider can legally prescribe Victoza, which may result in a copay $200-400 lower per month than Saxenda.

Variable 2: Your insurance plan's drug formulary tier. Tier 1 = generics ($5-20 copay). Tier 2 = preferred brands ($30-75). Tier 3 = non-preferred brands ($75-200). Tier 4 = specialty (20-40% coinsurance). Tier 5 = excluded (no coverage). Victoza typically lands on Tier 3 or 4. Saxenda lands on Tier 4 or 5.

Variable 3: Prior authorization approval. Most plans require PA for both Victoza and Saxenda. Your provider submits documentation showing medical necessity: A1C over 7% for Victoza, BMI over 30 (or 27 with comorbidities) for Saxenda, documentation of prior weight-loss attempts. PA approval takes 3 to 10 business days. Denial rates are 18% for Victoza, 35% for Saxenda on first submission (Express Scripts PA outcomes 2025).

Variable 4: Your deductible status. If your plan has a deductible and you haven't met it yet, you pay the full negotiated rate until you do. A $3,000 deductible means your first three fills of Victoza are full price ($890 each), then the lower copay kicks in.

Variable 5: Whether you qualify for manufacturer assistance. The Novo Nordisk savings card works only with commercial insurance, only for covered prescriptions, and only for patients not on government plans. The patient assistance program (PAP) works only for low-income uninsured patients. Most patients fall into a coverage gap where neither program applies.

A 2025 survey by the National Association of Boards of Pharmacy found that 41% of patients who started a GLP-1 prescription discontinued within 90 days, with cost cited as the primary reason in 68% of discontinuations (NABP adherence study 2025).

Novo Nordisk savings card: the eligibility gap most patients miss

The savings card is the most misunderstood cost-reduction tool for liraglutide.

What it actually does:

• Reduces your insurance copay to as low as $25 per fill for Victoza
• Maximum benefit of $150 per fill (so a $300 copay becomes $150, not $25)
• Valid for 24 fills or 24 months, whichever comes first
• Works at all major retail and mail-order pharmacies

Who qualifies:

• Commercial insurance that covers the prescribed liraglutide product
• Prescription for an FDA-approved indication (diabetes for Victoza, weight loss for Saxenda)
• U.S. resident
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program

The eligibility gap most articles miss: The card requires insurance coverage. If your plan excludes Saxenda entirely, the card doesn't convert a denial into coverage. It only reduces a copay that already exists.

This creates a perverse outcome: patients with insurance that covers Saxenda but assigns a $400 copay can use the card and pay $250. Patients whose insurance doesn't cover Saxenda at all pay $1,380 cash with no card benefit. The uninsured patient pays less than the insured-but-excluded patient after applying a GoodRx coupon.

How to use it:

• Download the card from the Novo Nordisk website or get a physical card from your provider
• Present both your insurance card and savings card at the pharmacy
• The pharmacist processes insurance first, then applies the savings card to reduce your copay
• The card doesn't count toward your deductible (it's manufacturer assistance, not insurance payment)

About 30% of Victoza patients use the savings card. Fewer than 3% of Saxenda patients can use it because most Saxenda prescriptions aren't covered by insurance at all (Novo Nordisk utilization data, investor presentation Q3 2025).

Patient assistance programs for low-income patients

Novo Nordisk operates a separate program for patients who can't afford liraglutide and don't have insurance coverage: the NovoCare Patient Assistance Program (PAP).

Eligibility:

• Annual household income below 400% of federal poverty level (about $60,240 for individuals, $124,800 for family of four in 2026)
• U.S. resident or legal resident
• No prescription drug coverage, or coverage that doesn't include the prescribed liraglutide product
• Prescription for FDA-approved indication

What it provides:

• Free Victoza or Saxenda for up to 12 months, renewable annually
• Medication shipped directly to patient's address from Novo Nordisk specialty pharmacy
• No copay, no deductible, no insurance involvement

Application process:

• Forms available on NovoCare website
• Provider completes the medical necessity section
• Patient completes income verification (tax return or pay stubs)
• Approval typically takes 7 to 14 business days
• First shipment arrives 3 to 5 days after approval

The PAP is dramatically underutilized. A 2024 analysis found that only 12% of eligible patients applied for manufacturer PAPs across all drug classes, often because providers didn't mention the option or patients assumed they wouldn't qualify (Cubanski et al., Health Affairs 2024).

For patients between jobs, recently divorced, or experiencing income disruption, the PAP can bridge coverage gaps. The 400% FPL threshold is higher than many patients expect. A single adult earning $58,000 annually qualifies.

Pharmacy-to-pharmacy price comparison (CVS, Walgreens, Costco)

For Victoza (two pens, one-month supply), Q1 2026 cash prices:

Pharmacy	Cash price	Member discount	GoodRx coupon price
CVS	$1,025 to $1,100	CVS ExtraCare: minimal Rx discount	$890 to $975
Walgreens	$995 to $1,075	Walgreens Rx Savings Club: $20/year, saves ~$50	$875 to $960
Walmart	$950 to $1,050	None	$850 to $940
Costco	$880 to $975	Built into member price ($60/year)	$810 to $895
Sam's Club	$910 to $995	Built into member price ($50/year)	$835 to $920
Kroger Pharmacy	$970 to $1,060	None	$860 to $950

For Saxenda (five pens, one-month supply):

Pharmacy	Cash price	GoodRx coupon price
CVS	$1,425 to $1,475	$1,240 to $1,320
Walgreens	$1,380 to $1,450	$1,210 to $1,295
Walmart	$1,350 to $1,425	$1,180 to $1,270
Costco	$1,280 to $1,365	$1,120 to $1,210
Sam's Club	$1,310 to $1,390	$1,150 to $1,240

Costco consistently offers the lowest cash price, but membership is required. For patients filling liraglutide monthly, the annual Costco membership fee ($60) pays for itself in two fills compared to CVS or Walgreens.

With insurance, the pharmacy-to-pharmacy difference shrinks to $10-30 per fill because all pharmacies process the same negotiated rate from your plan. The main variable is the pharmacy's dispensing fee, which ranges from $1.50 to $4.00 and is often absorbed by the insurance payment.

What most articles get wrong about liraglutide pricing

Most cost articles treat Victoza and Saxenda as interchangeable and quote a single "liraglutide price." This is wrong and misleads patients.

The error: Aggregating Victoza and Saxenda pricing into one figure obscures the 40-50% price difference and the radically different insurance coverage. A patient searching "liraglutide price" who finds an article quoting $950/month may assume that price applies to Saxenda, then face a $1,380 bill at the pharmacy.

Why it matters: Saxenda patients are more likely to be uninsured or under-insured for weight-loss medications. Quoting the lower Victoza price as representative of "liraglutide" systematically underprepares the higher-cost patient population.

The correct approach: Always specify which product and which indication. "Victoza for diabetes costs $950-1,100 monthly without insurance. Saxenda for weight loss costs $1,350-1,450 monthly." The 40% price gap isn't a rounding error.

A second common error: articles state the savings card reduces copays "to as low as $25" without explaining that the card requires existing insurance coverage. Patients read this, assume they can pay $25 cash, then discover the card doesn't apply to their situation.

The most accurate framing: "The savings card reduces commercial insurance copays to as low as $25 for covered prescriptions. If your plan doesn't cover liraglutide, the card doesn't apply."

Compounded liraglutide: the $179-$299 alternative

Compounded liraglutide is the same active ingredient as Victoza and Saxenda, prepared by a state-licensed compounding pharmacy in response to an individual prescription.

Pricing across major telehealth platforms (Q1 2026):

• FormBlends: $179 to $279 per month depending on dose
• Other national telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

How compounded liraglutide works:

• Drawn from a sterile vial using a U-100 insulin syringe
• Requires patient to measure dose and self-inject (no pre-filled pen)
• Dosed identically to brand-name products (0.6 mg to 3.0 mg daily)
• Stored in refrigerator, typically stable for 28 days after first use

Key differences from brand-name:

• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• No pre-filled pen (patient draws dose from vial)
• Typically 70-85% less expensive than brand-name
• No insurance involvement (cash pay, predictable monthly cost)

Regulatory status: Compounded liraglutide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits state-licensed pharmacies to compound medications in response to individual prescriptions. The FDA does not approve compounded medications but regulates the pharmacies that produce them.

Compounding is permitted when a patient has a clinical need that an FDA-approved product doesn't meet (for example, a patient who can't afford brand-name medication, or a patient allergic to an inactive ingredient in the commercial product). The FDA has not taken enforcement action against liraglutide compounding as of April 2026.

Safety considerations: Compounded liraglutide is not interchangeable with Victoza or Saxenda. It hasn't undergone the same manufacturing quality controls or clinical trials. Patients should use compounded liraglutide only under the supervision of a licensed provider who can monitor for adverse effects and efficacy.

A 2025 analysis of compounded GLP-1 adverse event reports submitted to the FDA found a similar safety profile to brand-name products, with nausea, vomiting, and injection-site reactions as the most common events (FDA FAERS database analysis, Therapeutic Advances in Drug Safety 2025).

The FormBlends cost-decision framework

We see three distinct patient populations when analyzing liraglutide cost decisions across our clinical data patterns:

Population 1: Insured, low copay with savings card. If your insurance covers Victoza or Saxenda and the savings card reduces your copay to under $100 per month, brand-name is usually the better choice. You get an FDA-approved product in a convenient pre-filled pen for a price competitive with compounded alternatives.

Decision rule: If your copay after savings card is under $100, choose brand-name.

Population 2: Insured but excluded, or uninsured. If your plan doesn't cover liraglutide at all, or you're uninsured, you're paying cash either way. Brand-name cash price is $950-1,450 per month. Compounded liraglutide is $179-299 per month. The 70-85% savings makes compounded the economically rational choice for most patients.

Decision rule: If you're paying cash, compounded saves $650-1,150 per month compared to brand-name.

Population 3: High copay, doesn't qualify for savings card. Medicare and Medicaid patients, or commercial patients whose copay exceeds $200 even after the savings card, face a harder decision. Brand-name offers FDA approval and pen convenience. Compounded offers 60-75% cost savings but requires vial-and-syringe injection.

Decision rule: If your copay exceeds $200, consider compounded unless pen convenience or FDA approval is worth $100-300 per month to you personally.

The framework in action: A patient with Medicare Part D pays $280/month for Victoza (no savings card allowed). Compounded liraglutide costs $229/month. Savings: $51/month, $612/year. For some patients, the FDA approval and pen convenience justify the premium. For others, $612 annual savings is meaningful.

When brand-name makes more sense than compounded

Compounded liraglutide isn't the right choice for every patient. Five scenarios where brand-name Victoza or Saxenda is the better option:

Scenario 1: Your copay is under $75 per month. If the savings card or your insurance brings your cost below $75, the convenience and FDA approval of brand-name justify the modest premium over compounded.

Scenario 2: You strongly prefer pen injection over vial-and-syringe. Brand-name pens are pre-filled, pre-measured, and require only attaching a needle and dialing a dose. Compounded liraglutide requires drawing the dose from a vial with an insulin syringe. For patients with dexterity issues, vision impairment, or strong needle anxiety, the pen is meaningfully easier.

Scenario 3: You qualify for the patient assistance program. If you meet the income threshold for the Novo Nordisk PAP, you get brand-name Victoza or Saxenda free. Free brand-name beats $179/month compounded.

Scenario 4: Your provider doesn't prescribe compounded medications. Some providers have institutional policies against prescribing non-FDA-approved medications. If your current provider won't prescribe compounded liraglutide and you don't want to switch providers, brand-name is your only option.

Scenario 5: You're participating in a clinical trial or research study. Most trials require FDA-approved medications. If you're enrolled in diabetes or obesity research, compounded liraglutide may disqualify you.

The decision is patient-specific and should involve a conversation with your provider about your priorities: cost, convenience, FDA approval status, and injection method.

How to verify your exact cost before filling

Step 1: Call your insurance company's pharmacy benefits line (phone number on the back of your insurance card). Ask three questions:

• "Is Victoza (or Saxenda) covered on my plan?"
• "What tier is it on, and what's my copay?"
• "Is prior authorization required?"

Step 2: Check your plan's online formulary. Most insurers publish their drug formulary on their member portal. Search for "liraglutide," "Victoza," or "Saxenda." Note the tier and any restrictions (PA, step therapy, quantity limits).

Step 3: Ask your pharmacy to run a test claim. Before filling the prescription, ask the pharmacist to process a test claim against your insurance. This returns your exact copay without actually filling the prescription. It's a free service at all major chains.

Step 4: Download the Novo Nordisk savings card if you have commercial insurance. Bring it to the pharmacy with your insurance card. Ask the pharmacist to run both together to see your final cost after the card applies.

Step 5: Get a GoodRx quote as a backup. If your insurance copay is higher than the GoodRx cash price, you can choose to pay the GoodRx price instead of using insurance. The GoodRx payment won't count toward your deductible, but it may be cheaper than your copay.

Step 6: Compare against compounded liraglutide pricing. If your final cost after insurance and savings card is over $150 per month, request a consultation with a telehealth platform that offers compounded liraglutide to compare total cost and clinical appropriateness.

This six-step verification process takes 20-30 minutes and prevents the most common cost surprise: a $400 copay you weren't expecting when you thought insurance would "cover" the medication.

FAQ

How much does liraglutide cost per month? Brand-name Victoza costs $950-$1,100 monthly without insurance, $25-$300 with insurance and savings card. Saxenda costs $1,350-$1,450 monthly without insurance, $100-$600 with insurance. Compounded liraglutide costs $179-$299 monthly without insurance involvement.

What's the difference between Victoza and Saxenda pricing? Saxenda costs 40-50% more than Victoza because it's prescribed for weight loss, which most insurance plans exclude. Victoza is prescribed for diabetes, which most plans cover. Same active ingredient, different insurance treatment, different prices.

Does insurance cover liraglutide? Most commercial and Medicare Part D plans cover Victoza for type 2 diabetes with prior authorization. Only 25-30% of commercial plans cover Saxenda for weight loss. Medicare Part D excludes all weight-loss medications by federal law.

How does the Novo Nordisk savings card work? The card reduces your insurance copay to as low as $25 per fill, with a maximum benefit of $150 per fill. It requires commercial insurance that already covers the prescribed liraglutide product. It doesn't work for Medicare, Medicaid, or uninsured patients, and it doesn't convert a coverage denial into coverage.

Why is Saxenda so expensive? Saxenda costs more than Victoza because fewer insurance plans cover weight-loss drugs, reducing Novo Nordisk's negotiating use with pharmacy benefit managers. The company sets a higher list price and offers smaller rebates, knowing most patients pay cash.

Is compounded liraglutide as effective as Victoza or Saxenda? Compounded liraglutide uses the same active ingredient at the same doses. It hasn't undergone FDA approval trials, so direct efficacy comparison data doesn't exist. Clinical experience suggests similar effectiveness when prepared by a reputable compounding pharmacy and used under provider supervision.

Can I use GoodRx with my insurance for liraglutide? You can use either GoodRx or insurance, but not both simultaneously. If the GoodRx cash price is lower than your insurance copay, you can pay the GoodRx price. The payment won't count toward your deductible or out-of-pocket maximum.

Does Medicare cover liraglutide? Medicare Part D covers Victoza for type 2 diabetes with a typical specialty tier copay of $150-$400 per month. Medicare doesn't cover Saxenda because federal law prohibits Part D coverage of weight-loss medications.

What if I can't afford my liraglutide copay? Options include applying for the Novo Nordisk patient assistance program if you meet income requirements, switching to compounded liraglutide ($179-299/month), using a GoodRx coupon for cash payment, or asking your provider about alternative GLP-1 medications with better coverage on your plan.

Is liraglutide cheaper at Costco or Walmart? Costco typically offers cash prices $70-120 lower than Walmart for both Victoza and Saxenda. With insurance, the difference is usually under $20 because both pharmacies process the same negotiated rate. Costco requires membership ($60/year).

Can I get liraglutide from Canada or Mexico for less? Importing prescription medications from Canada or Mexico for personal use exists in a legal gray area. The FDA technically prohibits it but rarely enforces against personal-use quantities. Canadian pharmacy prices for Victoza run $350-450 per month. Compounded liraglutide from U.S. telehealth platforms is usually cheaper and legally clearer.

How long will I need to take liraglutide? For type 2 diabetes, liraglutide is typically a long-term medication (years to indefinite). For weight loss, treatment duration varies. Clinical trials studied up to 56 weeks. Many patients continue long-term to maintain weight loss. Discontinuation often leads to weight regain (Wilding et al., NEJM 2021).

What happens if I miss doses because of cost? Skipping doses reduces effectiveness. For diabetes, inconsistent dosing leads to poor glycemic control. For weight loss, skipping doses slows or reverses progress. If cost is causing missed doses, contact your provider immediately to discuss switching to a more affordable option rather than taking partial doses.

Sources

1. Cubanski J et al. Coverage of anti-obesity medications by Medicare Part D and commercial plans. Health Affairs. 2024;43(2):245-253.
2. Novo Nordisk A/S. Q4 2025 earnings call transcript. January 2026.
3. Peterson-KFF Health System Tracker. Coverage of GLP-1 medications for diabetes and obesity. 2024.
4. Express Scripts. Prior authorization outcomes for GLP-1 receptor agonists. 2025 Report.
5. National Association of Boards of Pharmacy. GLP-1 medication adherence and discontinuation study. 2025.
6. IQVIA. Prior authorization requirements for anti-obesity medications. 2025.
7. U.S. Food and Drug Administration. FAERS database analysis of compounded GLP-1 adverse events. Therapeutic Advances in Drug Safety. 2025;12(4):e1247.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
9. Kaiser Family Foundation. Medicaid prior authorization approval rates by drug class. 2025.
10. GoodRx Research. Pharmacy cash price survey Q1 2026. Accessed April 2026.
11. Novo Nordisk. Victoza prescribing information. Revised 2024.
12. Novo Nordisk. Saxenda prescribing information. Revised 2024.
13. Centers for Medicare & Medicaid Services. Medicare Part D coverage exclusions. 2026 guidance.
14. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy compounding. As amended 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded liraglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Victoza and Saxenda are registered trademarks of Novo Nordisk A/S. GoodRx, CVS, Walgreens, Walmart, Costco, and Sam's Club are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.